×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IMVT – immunovant, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IMVT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/13
09:45 am
imvt
Prevent Blindness Declares Fifth Annual Thyroid Eye Disease Awareness Week as Nov. 18-24, 2024
Medium
Report
Prevent Blindness Declares Fifth Annual Thyroid Eye Disease Awareness Week as Nov. 18-24, 2024
11/8
11:57 am
imvt
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus [Yahoo! Finance]
Low
Report
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus [Yahoo! Finance]
11/8
08:46 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
11/7
06:30 am
imvt
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
Low
Report
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
10/29
06:30 am
imvt
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
Low
Report
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
10/14
02:58 pm
imvt
Immunovant: Switching Lead Candidates Increases Risk [Seeking Alpha]
Low
Report
Immunovant: Switching Lead Candidates Increases Risk [Seeking Alpha]
10/10
09:36 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $36.00 price target on the stock.
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $36.00 price target on the stock.
10/9
08:40 am
imvt
Immunovant, Inc. (NASDAQ: IMVT) had its price target raised by analysts at Oppenheimer Holdings Inc. from $47.00 to $53.00. They now have an "outperform" rating on the stock.
Low
Report
Immunovant, Inc. (NASDAQ: IMVT) had its price target raised by analysts at Oppenheimer Holdings Inc. from $47.00 to $53.00. They now have an "outperform" rating on the stock.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/12
10:33 am
imvt
Form SC 13G/A Immunovant, Inc. Filed by: FMR LLC
Low
Report
Form SC 13G/A Immunovant, Inc. Filed by: FMR LLC
11/7
06:50 am
imvt
Form 10-Q Immunovant, Inc. For: Sep 30
Low
Report
Form 10-Q Immunovant, Inc. For: Sep 30
11/7
06:42 am
imvt
Form 8-K Immunovant, Inc. For: Nov 07
Low
Report
Form 8-K Immunovant, Inc. For: Nov 07
10/25
04:25 pm
imvt
Form 4 Immunovant, Inc. For: Oct 23 Filed by: Levine Mark S.
Low
Report
Form 4 Immunovant, Inc. For: Oct 23 Filed by: Levine Mark S.
10/25
04:24 pm
imvt
Form 4 Immunovant, Inc. For: Oct 23 Filed by: Geffner Michael
Low
Report
Form 4 Immunovant, Inc. For: Oct 23 Filed by: Geffner Michael
10/25
04:22 pm
imvt
Form 4 Immunovant, Inc. For: Oct 23 Filed by: Stout Jay S
Low
Report
Form 4 Immunovant, Inc. For: Oct 23 Filed by: Stout Jay S
10/18
04:31 pm
imvt
Form 4 Immunovant, Inc. For: Oct 16 Filed by: Salzmann Peter
Low
Report
Form 4 Immunovant, Inc. For: Oct 16 Filed by: Salzmann Peter
10/18
04:30 pm
imvt
Form 4 Immunovant, Inc. For: Oct 16 Filed by: Macias William L.
Low
Report
Form 4 Immunovant, Inc. For: Oct 16 Filed by: Macias William L.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/30
Immunovant Announces Positive Clinical Results from Ongoing Phase 2a Proof-of-Concept Study of IMVT-1401, A Novel Investigational Anti-FcRn Antibody Delivered by Subcutaneous Injection, in Thyroid Eye Disease
23.1%
4/14 Immunovant Announces Pricing of $121.2 Million Public Offering 12.8%
12/19 Immunovant Sciences Ltd. Closes Transaction with Health Sciences Acquisitions Corporation 12.1%
1/9 Immunovant (NASDAQ: IMVT) is now covered by analysts at Chardan Capital. They set a "buy" rating on the stock. 6.9%
2/14 Immunovant Reports Financial Results for the Quarter and Nine Months Ending December 31, 2019 6.4%
2/14 Form SC 13G/A Immunovant, Inc. Filed by: Cormorant Asset Management, LP 5.7%
4/8 Form S-1/A Immunovant, Inc. 4.3%
1/10 Immunovant (NASDAQ: IMVT) is now covered by analysts at SunTrust Banks, Inc.. They set a "buy" rating on the stock. 3.8%
3/4 Immunovant (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Nomura. They now have a $27.00 price target on the stock. 3.3%
12/20 Form 4 Health Sciences Acquisit For: Dec 18 Filed by: Health Sciences Holdings, LLC 3.2%
4/14 Immunovant Announces Pricing of $121.2 Million Public Offering 12.8%
12/19 Immunovant Sciences Ltd. Closes Transaction with Health Sciences Acquisitions Corporation 12.1%
1/9 Immunovant (NASDAQ: IMVT) is now covered by analysts at Chardan Capital. They set a "buy" rating on the stock. 6.9%
2/14 Immunovant Reports Financial Results for the Quarter and Nine Months Ending December 31, 2019 6.4%
2/14 Form SC 13G/A Immunovant, Inc. Filed by: Cormorant Asset Management, LP 5.7%
4/8 Form S-1/A Immunovant, Inc. 4.3%
1/10 Immunovant (NASDAQ: IMVT) is now covered by analysts at SunTrust Banks, Inc.. They set a "buy" rating on the stock. 3.8%
3/4 Immunovant (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Nomura. They now have a $27.00 price target on the stock. 3.3%
12/20 Form 4 Health Sciences Acquisit For: Dec 18 Filed by: Health Sciences Holdings, LLC 3.2%
TOP News Decliners
2/12
Form SC 13G/A Immunovant, Inc. Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-7.3%
2/24 Immunovant (NASDAQ: IMVT) is now covered by analysts at Svb Leerink Llc. They set an "outperform" rating and a $24.00 price target on the stock. -6.0%
3/30 Form 8-K Immunovant, Inc. For: Mar 30 -6.0%
1/17 Form S-1 Immunovant, Inc. -5.5%
2/19 Form 3 Immunovant, Inc. For: Feb 18 Filed by: Venker Eric -3.8%
2/21 Immunovant (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Chardan Capital. -2.8%
2/5 Immunovant (NASDAQ: IMVT) is now covered by analysts at Nomura. They set a "buy" rating and a $27.00 price target on the stock. -2.8%
4/16 Immunovant Announces Closing of $139.4 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares -2.1%
2/10 Immunovant to Present at the 9th Annual SVB Leerink Global Healthcare Conference -2.0%
1/7 Immunovant (NASDAQ: IMVT) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. -1.9%
2/24 Immunovant (NASDAQ: IMVT) is now covered by analysts at Svb Leerink Llc. They set an "outperform" rating and a $24.00 price target on the stock. -6.0%
3/30 Form 8-K Immunovant, Inc. For: Mar 30 -6.0%
1/17 Form S-1 Immunovant, Inc. -5.5%
2/19 Form 3 Immunovant, Inc. For: Feb 18 Filed by: Venker Eric -3.8%
2/21 Immunovant (NASDAQ: IMVT) had its "buy" rating re-affirmed by analysts at Chardan Capital. -2.8%
2/5 Immunovant (NASDAQ: IMVT) is now covered by analysts at Nomura. They set a "buy" rating and a $27.00 price target on the stock. -2.8%
4/16 Immunovant Announces Closing of $139.4 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares -2.1%
2/10 Immunovant to Present at the 9th Annual SVB Leerink Global Healthcare Conference -2.0%
1/7 Immunovant (NASDAQ: IMVT) is now covered by analysts at Robert W. Baird. They set an "outperform" rating on the stock. -1.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: